NEW YORK (GenomeWeb News) – Molecular diagnostics company AdvanDx announced today that it has received clearance from the US Food and Drug Administration for a 90-minute version of its peptide nucleic acid fluorescence in situ hybridization (PNA FISH) test for the bloodstream pathogen Enterococcus faecalis.

AdvanDx secured FDA 510(k) clearance for the test, which is faster than the existing two-and-a-half hour E. faecalis PNA FISH test but appears to have similar sensitivity and specificity, based on clinical validation studies in the US and Europe.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.